Insulet Co. (NASDAQ:PODD) EVP Bradley A. Thomas sold 7,250 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $83.81, for a total value of $607,622.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Bradley A. Thomas also recently made the following trade(s):
- On Friday, March 16th, Bradley A. Thomas sold 3,500 shares of Insulet stock. The shares were sold at an average price of $85.00, for a total value of $297,500.00.
PODD stock opened at $83.77 on Monday. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. The company has a market cap of $4,891.41, a P/E ratio of -182.11 and a beta of 1.38. Insulet Co. has a 1-year low of $38.43 and a 1-year high of $88.88.
Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $130.50 million for the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. equities analysts forecast that Insulet Co. will post -0.29 EPS for the current year.
Several hedge funds have recently bought and sold shares of the stock. Rehmann Capital Advisory Group acquired a new position in shares of Insulet during the 4th quarter worth approximately $375,000. Xact Kapitalforvaltning AB acquired a new position in shares of Insulet during the 4th quarter worth approximately $381,000. Segall Bryant & Hamill LLC increased its holdings in shares of Insulet by 10.5% during the 4th quarter. Segall Bryant & Hamill LLC now owns 200,707 shares of the medical instruments supplier’s stock worth $13,849,000 after acquiring an additional 19,105 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of Insulet during the 4th quarter worth approximately $1,804,000. Finally, Castleark Management LLC acquired a new position in shares of Insulet during the 4th quarter worth approximately $16,289,000.
Several research firms have commented on PODD. BidaskClub upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 23rd. Guggenheim began coverage on Insulet in a research note on Tuesday, April 3rd. They issued a “buy” rating and a $105.00 target price on the stock. ValuEngine upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. Finally, Barclays reiterated an “overweight” rating and set a $90.00 price objective (up previously from $85.00) on shares of Insulet in a research note on Thursday, February 22nd. Seven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $75.00.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Insulet Co. (NASDAQ:PODD) EVP Sells 7,250 Shares of Stock” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/insulet-co-podd-evp-bradley-a-thomas-sells-7250-shares-of-stock.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.